JP2015526391A - 抗ｉ型インターフェロン受容体（ｉｆｎａｒ）抗体のための固定用量レジメン - Google Patents

抗ｉ型インターフェロン受容体（ｉｆｎａｒ）抗体のための固定用量レジメン Download PDF

Info

Publication number
JP2015526391A
JP2015526391A JP2015517382A JP2015517382A JP2015526391A JP 2015526391 A JP2015526391 A JP 2015526391A JP 2015517382 A JP2015517382 A JP 2015517382A JP 2015517382 A JP2015517382 A JP 2015517382A JP 2015526391 A JP2015526391 A JP 2015526391A
Authority
JP
Japan
Prior art keywords
ifn
type
patient
antibody
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015517382A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015526391A5 (enExample
Inventor
ヒッグズ，ブランドン
ヤオ，イホン
ワン，ビン
ロスコス，ローリン
チャン，リンダ
Original Assignee
メディミューン，エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49758685&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2015526391(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by メディミューン，エルエルシー filed Critical メディミューン，エルエルシー
Publication of JP2015526391A publication Critical patent/JP2015526391A/ja
Publication of JP2015526391A5 publication Critical patent/JP2015526391A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G06—COMPUTING OR CALCULATING; COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N7/00—Computing arrangements based on specific mathematical models
    • G06N7/01—Probabilistic graphical models, e.g. probabilistic networks
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Data Mining & Analysis (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Theoretical Computer Science (AREA)
  • Primary Health Care (AREA)
  • Databases & Information Systems (AREA)
  • General Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Mathematical Physics (AREA)
  • Software Systems (AREA)
JP2015517382A 2012-06-13 2013-06-12 抗ｉ型インターフェロン受容体（ｉｆｎａｒ）抗体のための固定用量レジメン Pending JP2015526391A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261659138P 2012-06-13 2012-06-13
US61/659,138 2012-06-13
PCT/US2013/045327 WO2013188494A1 (en) 2012-06-13 2013-06-12 Fixed dosage regimens for anti-type i interferon receptor (ifnar) antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017231307A Division JP2018065845A (ja) 2012-06-13 2017-12-01 抗ｉ型インターフェロン受容体（ｉｆｎａｒ）抗体のための固定用量レジメン

Publications (2)

Publication Number Publication Date
JP2015526391A true JP2015526391A (ja) 2015-09-10
JP2015526391A5 JP2015526391A5 (enExample) 2016-07-14

Family

ID=49758685

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2015517382A Pending JP2015526391A (ja) 2012-06-13 2013-06-12 抗ｉ型インターフェロン受容体（ｉｆｎａｒ）抗体のための固定用量レジメン
JP2017231307A Pending JP2018065845A (ja) 2012-06-13 2017-12-01 抗ｉ型インターフェロン受容体（ｉｆｎａｒ）抗体のための固定用量レジメン
JP2019033979A Active JP6814238B2 (ja) 2012-06-13 2019-02-27 抗ｉ型インターフェロン受容体（ｉｆｎａｒ）抗体のための固定用量レジメン
JP2020174325A Ceased JP2021042208A (ja) 2012-06-13 2020-10-16 抗ｉ型インターフェロン受容体（ｉｆｎａｒ）抗体のための固定用量レジメン
JP2021112707A Active JP7123225B2 (ja) 2012-06-13 2021-07-07 抗ｉ型インターフェロン受容体（ｉｆｎａｒ）抗体のための固定用量レジメン

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2017231307A Pending JP2018065845A (ja) 2012-06-13 2017-12-01 抗ｉ型インターフェロン受容体（ｉｆｎａｒ）抗体のための固定用量レジメン
JP2019033979A Active JP6814238B2 (ja) 2012-06-13 2019-02-27 抗ｉ型インターフェロン受容体（ｉｆｎａｒ）抗体のための固定用量レジメン
JP2020174325A Ceased JP2021042208A (ja) 2012-06-13 2020-10-16 抗ｉ型インターフェロン受容体（ｉｆｎａｒ）抗体のための固定用量レジメン
JP2021112707A Active JP7123225B2 (ja) 2012-06-13 2021-07-07 抗ｉ型インターフェロン受容体（ｉｆｎａｒ）抗体のための固定用量レジメン

Country Status (9)

Country Link
US (1) US9493570B2 (enExample)
EP (1) EP2861621A4 (enExample)
JP (5) JP2015526391A (enExample)
KR (3) KR102320059B1 (enExample)
CN (3) CN104603152A (enExample)
AU (3) AU2013274389A1 (enExample)
CA (1) CA2876636C (enExample)
HK (1) HK1209758A1 (enExample)
WO (1) WO2013188494A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024511227A (ja) * 2021-04-23 2024-03-12 アストラゼネカ・アクチエボラーグ 皮下注射のための抗ｉｆｎａｒ１投薬計画
JP2024518735A (ja) * 2021-04-23 2024-05-02 アストラゼネカ・アクチエボラーグ 抗ｉ型ｉｎｆ受容体抗体アニフロルマブによるループス腎炎の治療

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7662381B2 (en) * 2004-06-21 2010-02-16 Medarex, Inc. Interferon alpha receptor 1 antibodies and their uses
KR100680048B1 (ko) * 2006-01-23 2007-02-08 쌍용자동차 주식회사 자동차 도장용 크레인의 구조
US20180305761A1 (en) * 2015-10-09 2018-10-25 Genefron Ltd. METHODS AND KITS FOR PREDICTION AND DIAGNOSIS OF HUMAN CYTOMEGALOVIRUS (hCMV) CONGENITAL TRANSMISSION
CA3029627A1 (en) 2016-07-01 2018-01-04 Resolve Therapeutics, Llc Optimized binuclease fusions and methods
CN106243226B (zh) * 2016-08-05 2019-02-12 北京智仁美博生物科技有限公司 抗人ifnar1的抗体及其用途
EP3601352B1 (en) 2017-03-21 2021-02-17 Austrianni GmbH Type 1 interferon receptor antagonists for use in methods of treating tuberculosis and other infectious diseases
JP7374091B2 (ja) 2017-08-22 2023-11-06 サナバイオ， エルエルシー 可溶性インターフェロン受容体およびその使用
US11139051B2 (en) * 2018-10-02 2021-10-05 Origent Data Sciences, Inc. Systems and methods for designing clinical trials
CN113692287A (zh) * 2018-10-26 2021-11-23 詹森生物科技公司 I型干扰素标记及使用方法
US20220144957A1 (en) * 2019-01-31 2022-05-12 Immunecent Biotechnology, Inc. Novel anti-ifnar1 antibodies
CN111892653A (zh) * 2019-07-03 2020-11-06 长春恒晓生物科技有限责任公司 制备粘病毒抗性蛋白1抗体及建立检测mx1方法
WO2025022280A1 (en) 2023-07-21 2025-01-30 Astrazeneca Ab Treatment of neurodegenerative diseases
GB202402824D0 (en) * 2024-02-28 2024-04-10 Astrazeneca Ab Treatment of chronic kidney disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011514150A (ja) * 2008-02-08 2011-05-06 メディミューン，エルエルシー 低下したＦｃリガンド親和性を有する抗ＩＦＮＡＲ１抗体

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002069904A2 (en) * 2001-03-02 2002-09-12 Medimmune, Inc. Cd2 antagonists for treatment of autoimmune or inflammatory disease
US20040037809A1 (en) * 2002-06-28 2004-02-26 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon beta
US7662381B2 (en) * 2004-06-21 2010-02-16 Medarex, Inc. Interferon alpha receptor 1 antibodies and their uses
WO2006128210A1 (en) * 2005-06-03 2006-12-07 John Arthur Notaras A tiller
EP1907858A4 (en) 2005-06-13 2009-04-08 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
WO2008093166A2 (en) * 2006-05-11 2008-08-07 Ghent University Sialoadhesin-related compositions and methods
CN101594882A (zh) * 2006-12-06 2009-12-02 米迪缪尼有限公司 干扰素α诱导的药代动力学标记物
RU2527068C2 (ru) * 2006-12-06 2014-08-27 Медиммун, Ллк Фармакодинамические маркеры, индуцированные интерфероном альфа
NZ585064A (en) * 2007-11-05 2012-08-31 Medimmune Llc Methods of treating scleroderma
US20110287022A1 (en) * 2008-06-20 2011-11-24 Medlmmune, Llc Interferon alpha-induced pharmacodynamic markers
AU2009281721A1 (en) 2008-08-15 2010-02-18 Merrimack Pharmaceuticals, Inc. Methods and systems for predicting response of cells to a therapeutic agent
PL2473636T3 (pl) 2009-09-03 2017-05-31 Medimmune, Llc Diagnostyka interferonu typu 1

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011514150A (ja) * 2008-02-08 2011-05-06 メディミューン，エルエルシー 低下したＦｃリガンド親和性を有する抗ＩＦＮＡＲ１抗体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WANG, D.D. ET AL., J CLIN PHARMACOL, vol. 49, no. 9, JPN6016033501, 2009, pages 1012 - 24, ISSN: 0003608096 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024511227A (ja) * 2021-04-23 2024-03-12 アストラゼネカ・アクチエボラーグ 皮下注射のための抗ｉｆｎａｒ１投薬計画
JP2024518735A (ja) * 2021-04-23 2024-05-02 アストラゼネカ・アクチエボラーグ 抗ｉ型ｉｎｆ受容体抗体アニフロルマブによるループス腎炎の治療
JP7484027B2 (ja) 2021-04-23 2024-05-15 アストラゼネカ・アクチエボラーグ 皮下注射のための抗ｉｆｎａｒ１投薬計画
JP7746407B2 (ja) 2021-04-23 2025-09-30 アストラゼネカ・アクチエボラーグ 抗ｉ型ｉｎｆ受容体抗体アニフロルマブによるループス腎炎の治療

Also Published As

Publication number Publication date
AU2020204613B2 (en) 2021-10-07
AU2020204613A1 (en) 2020-07-30
JP7123225B2 (ja) 2022-08-22
US9493570B2 (en) 2016-11-15
AU2018206851C1 (en) 2021-11-25
KR20150035825A (ko) 2015-04-07
KR20210130270A (ko) 2021-10-29
KR20200133395A (ko) 2020-11-27
CN111494624A (zh) 2020-08-07
US20150158949A1 (en) 2015-06-11
JP2019112429A (ja) 2019-07-11
AU2018206851B2 (en) 2020-07-30
CN104603152A (zh) 2015-05-06
AU2018206851A1 (en) 2018-08-09
CA2876636C (en) 2022-09-13
KR102185237B9 (ko) 2021-08-06
JP2021167336A (ja) 2021-10-21
KR102320059B1 (ko) 2021-11-01
EP2861621A1 (en) 2015-04-22
JP2021042208A (ja) 2021-03-18
KR102185237B1 (ko) 2020-12-02
CN108310375A (zh) 2018-07-24
HK1209758A1 (en) 2016-04-08
CA2876636A1 (en) 2013-12-19
AU2013274389A1 (en) 2015-01-22
WO2013188494A1 (en) 2013-12-19
JP2018065845A (ja) 2018-04-26
JP6814238B2 (ja) 2021-01-13
EP2861621A4 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
JP7123225B2 (ja) 抗ｉ型インターフェロン受容体（ｉｆｎａｒ）抗体のための固定用量レジメン
KR101532797B1 (ko) 인터페론 알파 유도성 약력학적 마커
JP2018535394A (ja) Ｉｌ２３経路バイオマーカーを使用するｉｌ２３アンタゴニストに対する臨床応答の予測
CA2686861A1 (en) Interferon alpha-induced pharmacodynamic markers
JP2015504430A (ja) Ｉｌ−７アンタゴニスト及びｐｓａ応答又は非応答対立遺伝子を用いた乾癬性関節炎（ｐｓａ）を治療する方法
CA2836926A1 (en) Methods of treating systemic lupus erythematosus, scleroderma, and myositis with an antibody against interferon-alpha
KR20180096633A (ko) Il23-길항제에 대한 임상적 반응의 예측인자로서의 ccl20
TW202229334A (zh) CD1a抗體及其用途
AU2020222262B2 (en) Type I interferon-mediated disorders
HK40034632A (en) Fixed dosage regimens for anti-type i interferon receptor (ifnar) antibodies
AU2012258819A1 (en) Methods of treating systemic lupus erythematosus, scleroderma, and myositis with an antibody against interferon-alpha

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160519

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160519

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170117

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170411

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170801